查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2020322

單株抗體療法市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類的洞察，2026-2034 年預測

Monoclonal Antibody Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 135 Pages | 商品交期: 請詢問到貨日

價格

單株抗體（mAb）療法市場的成長要素

受標靶治療需求成長和生物技術進步的推動，全球單株抗體（mAb）療法市場正經歷快速擴張。預計該市場規模在2025年將達到3,006.7億美元，2026年將成長至3,439.9億美元，到2034年將達到1.05775兆美元，預測期內複合年成長率高達15.07%。

單株抗體是一種高度特異性的治療方法，用於治療癌症、自體免疫疾病和感染疾病等慢性疾病。它們能夠靶向特定細胞並最大限度地減少副作用，因此在全球範圍內得到了廣泛應用。預計到2025年，在強大的研發投入和先進的醫療基礎設施的支持下，北美將以48.00%的市場佔有率佔據主導地位。

市場趨勢

塑造市場格局的關鍵趨勢之一是製藥公司之間日益增多的策略合作夥伴關係，旨在開發創新單株抗體療法。生物技術公司與大型製藥公司之間的這些合作正在加速藥物的發現和商業化。

另一個主要趨勢是生物相似藥的快速擴張。隨著重磅藥物專利到期，價格較低的生物相似藥進入市場，提高了藥物可近性，也加劇了市場競爭。此外，新冠疫情加速了單株抗體療法的研發和緊急核准，進一步推動了市場成長。

市場促進因素

加大對新型治療藥物的投資

政府機構和私人組織的大量投資正在推動單株抗體療法的創新。資助舉措和研發項目正在支持開發療效較佳的新一代生物製藥。

慢性病盛行率增加

癌症和自體免疫疾病等慢性疾病負擔日益加重是推動單株抗體成長要素。單株抗體因其定向和有效性而成為首選治療方法。

像阿達木單抗（Humira）、Herceptin）和Rituxan）這樣的熱門藥物取得了巨大的銷售成功，極大地促進了市場擴張。

優惠的還款政策

已開發國家和新興國家醫療報銷制度的改善，增加了病患獲得昂貴生物製藥的機會，進一步刺激了需求。

市場限制

儘管預計市場將保持強勁成長，但由於嚴格的監管核准流程，市場仍面臨挑戰。單株抗體的研發和核准涉及複雜的臨床試驗和嚴格的品質標準，這會導致時間和成本的增加。

此外，潛在的副作用和高昂的製造成本限制了這些治療方法的廣泛應用，尤其是在價格敏感的地區。

細分分析

按類型

市場細分包括人源單株抗體、人源化單株抗體、嵌合單株嵌合體和鼠源單株抗體。預計到2026年，人源單株抗體細分市場將成為市場主導力量，佔據42.40%的市場佔有率，這主要得益於強勁的需求和關鍵生物製藥產品的良好銷售。

透過使用

預計到2026年，癌症領域將佔據最大佔有率，達到54.46%，這主要得益於全球癌症發生率的上升和抗癌藥物研發管線的持續擴充。自體免疫疾病和其他治療領域也呈現穩定成長的態勢。

透過分銷管道

預計到2026年，醫院藥局將以57.31%的市佔率引領市場。這主要歸功於更完善的報銷機制以及對這些藥物進行專業管理的需求。零售藥局和網路藥局也逐漸擴大市場佔有率。

區域趨勢

由於高額的醫療保健支出和強大的研究生態系統，預計到 2025 年，北美將引領市場，市場規模將達到 1,443.2 億美元。

在有利的監管政策和生物相似藥日益普及的推動下，預計到 2025 年，歐洲的市場規模將達到 676.1 億美元。

亞太地區是成長最快的地區，預計到 2025 年將達到 509.9 億美元。這主要得益於醫療保健領域的投資增加、疾病流行率上升以及患者人數不斷擴大。

拉丁美洲（2025 年為 216.3 億美元）和中東及非洲（2025 年為 161.2 億美元）是新興市場，由於醫療基礎設施的改善，這些市場呈現穩定成長的態勢。

生物相似藥的普及、技術的進步以及有利的醫療保險政策將進一步加速市場擴張。然而，監管方面的挑戰和高昂的治療費用仍然是主要問題。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 主要疾病流行情形：依主要國家分類，2025 年
  • 主要企業專利概覽
  • 主要企業管道分析
  • 新產品發布：按主要企業分類
  • 關鍵產業趨勢－併購與合作
  • 新冠疫情對市場的影響

第5章：全球單株抗體療法市場分析、洞察與預測（2021-2034年）

  • 市場分析、洞察與預測：按類型
    • 人源單株抗體
    • 人源化單株抗體
    • 嵌合體單株抗體
    • 小鼠來源的單株抗體
  • 市場分析、洞察與預測：按應用領域分類
    • 癌症
    • 自體免疫疾病
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥房
    • 網路藥房
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美單株抗體療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲單株抗體療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區單株抗體療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲單株抗體療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲單株抗體療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • 南非
    • GCC
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • AbbVie Inc.
    • Merck & Co., Inc
    • F.Hoffmann-La Roche Ltd.
    • Bristol-Myers Squibb Company
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • Daiichi Sankyo Company, Limited
    • Amgen Inc.
    • AstraZeneca
Product Code: FBI102734

Growth Factors of monoclonal antibody (mAb) therapy Market

The global monoclonal antibody (mAb) therapy market is experiencing rapid expansion driven by rising demand for targeted therapies and advancements in biotechnology. The market was valued at USD 300.67 billion in 2025 and is projected to grow to USD 343.99 billion in 2026, reaching USD 1,057.75 billion by 2034, exhibiting a strong CAGR of 15.07% during the forecast period.

Monoclonal antibodies are highly specific therapies used to treat chronic diseases such as cancer, autoimmune disorders, and infectious diseases. Their ability to target specific cells with minimal side effects has significantly increased their adoption globally. In 2025, North America dominated the market with a 48.00% share, supported by strong R&D investments and advanced healthcare infrastructure.

Market Trends

A key trend shaping the market is the growing number of strategic collaborations among pharmaceutical companies to develop innovative monoclonal antibody therapies. Partnerships between biotech firms and large pharmaceutical companies are accelerating drug discovery and commercialization.

Another major trend is the rapid expansion of biosimilars. As patents for blockbuster drugs expire, lower-cost biosimilars are entering the market, increasing accessibility and competition. Additionally, the COVID-19 pandemic accelerated research and emergency approvals for mAb therapies, further strengthening market growth.

Market Drivers

Rising Investment in Novel Therapeutics

Significant investments from both government bodies and private organizations are fueling innovation in monoclonal antibody therapies. Funding initiatives and R&D programs are supporting the development of next-generation biologics with improved efficacy.

Increasing Prevalence of Chronic Diseases

The growing burden of chronic diseases such as cancer and autoimmune disorders is a major growth driver. Monoclonal antibodies have become a preferred treatment due to their targeted action and effectiveness.

Popular drugs such as Humira, Herceptin, and Rituxan have achieved blockbuster status, significantly contributing to market expansion.

Favorable Reimbursement Policies

Improving healthcare reimbursement frameworks across developed and emerging economies are enhancing patient access to expensive biologic therapies, further boosting demand.

Market Restraints

Despite strong growth, the market faces challenges due to stringent regulatory approval processes. The development and approval of monoclonal antibodies involve complex clinical trials and strict quality standards, increasing time and cost.

Additionally, potential side effects and high manufacturing costs limit widespread adoption, particularly in price-sensitive regions.

Segmentation Analysis

By Type

The market is segmented into human, humanized, chimeric, and murine monoclonal antibodies. The human mAb segment dominated with a 42.40% share in 2026, driven by high demand and strong sales of leading biologics.

By Application

The cancer segment held the largest share of 54.46% in 2026, supported by the rising global cancer burden and increasing pipeline of oncology drugs. Autoimmune diseases and other therapeutic areas are also witnessing steady growth.

By Distribution Channel

The hospital pharmacy segment dominated with a 57.31% share in 2026, owing to better reimbursement policies and the need for professional administration of these therapies. Retail and online pharmacies are gradually expanding their presence.

Regional Insights

North America led the market with USD 144.32 billion in 2025, supported by high healthcare spending and strong research ecosystem.

Europe accounted for USD 67.61 billion in 2025, driven by favorable regulatory policies and increased adoption of biosimilars.

Asia Pacific is the fastest-growing region, with USD 50.99 billion in 2025, fueled by rising healthcare investments, increasing disease prevalence, and expanding patient base.

Latin America (USD 21.63 billion in 2025) and Middle East & Africa (USD 16.12 billion in 2025) are emerging markets showing steady growth due to improving healthcare infrastructure.

Competitive Landscape

The market is highly competitive, with major players such as AbbVie Inc., F. Hoffmann-La Roche Ltd., Amgen Inc., and Novartis AG.

These companies focus on product innovation, biosimilar development, and strategic partnerships to strengthen their market position. Collaborations and acquisitions are key strategies to expand therapeutic pipelines and global reach.

Conclusion

The monoclonal antibody therapy market is set for remarkable growth, expanding from USD 300.67 billion in 2025 to USD 1,057.75 billion by 2034. The market is driven by rising chronic disease prevalence, strong R&D investments, and increasing adoption of targeted therapies.

The growing availability of biosimilars, technological advancements, and favorable reimbursement policies will further accelerate market expansion. However, regulatory challenges and high treatment costs remain key concerns.

Segmentation By Type

  • Human mAb
  • Humanized mAb
  • Chimeric mAb
  • Murine mAb

By Application

  • Cancer
  • Autoimmune Diseases
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America (Type, Application, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (Type, Application, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia-Pacific (Type, Application, Distribution Channel, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (Type, Application, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (Type, Application, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases, by Key Countries/Region, 2025
  • 4.2. Patent Snapshot, by Key Players
  • 4.3. Pipeline Analysis, by Key Players
  • 4.4. New Product Launches, by Key Players
  • 4.5. Key Industry Developments - Mergers, Acquisitions and Partnerships
  • 4.6. Impact of COVID-19 on the Market

5. Global Monoclonal Antibody Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Human mAb
    • 5.1.2. Humanized mAb
    • 5.1.3. Chimeric mAb
    • 5.1.4. Murine mAb
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Cancer
    • 5.2.2. Autoimmune Diseases
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacy
    • 5.3.2. Retail Pharmacy
    • 5.3.3. Online Pharmacy
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Monoclonal Antibody Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Human mAb
    • 6.1.2. Humanized mAb
    • 6.1.3. Chimeric mAb
    • 6.1.4. Murine mAb
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Cancer
    • 6.2.2. Autoimmune Diseases
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacy
    • 6.3.2. Retail Pharmacy
    • 6.3.3. Online Pharmacy
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Monoclonal Antibody Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Human mAb
    • 7.1.2. Humanized mAb
    • 7.1.3. Chimeric mAb
    • 7.1.4. Murine mAb
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Cancer
    • 7.2.2. Autoimmune Diseases
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail Pharmacy
    • 7.3.3. Online Pharmacy
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Monoclonal Antibody Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Human mAb
    • 8.1.2. Humanized mAb
    • 8.1.3. Chimeric mAb
    • 8.1.4. Murine mAb
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Cancer
    • 8.2.2. Autoimmune Diseases
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacy
    • 8.3.2. Retail Pharmacy
    • 8.3.3. Online Pharmacy
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Monoclonal Antibody Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Human mAb
    • 9.1.2. Humanized mAb
    • 9.1.3. Chimeric mAb
    • 9.1.4. Murine mAb
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Cancer
    • 9.2.2. Autoimmune Diseases
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Monoclonal Antibody Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Human mAb
    • 10.1.2. Humanized mAb
    • 10.1.3. Chimeric mAb
    • 10.1.4. Murine mAb
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Cancer
    • 10.2.2. Autoimmune Diseases
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail Pharmacy
    • 10.3.3. Online Pharmacy
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub region
    • 10.4.1. South Africa
    • 10.4.2. GCC
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. AbbVie Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Merck & Co., Inc
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. F.Hoffmann-La Roche Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Bristol-Myers Squibb Company
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Johnson & Johnson Services, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Novartis AG
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Daiichi Sankyo Company, Limited
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Amgen Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. AstraZeneca
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 2: Global Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Application, 2021-2034
  • Table 3: Global Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Region, 2021-2034
  • Table 5: North America Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 6: North America Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Application, 2021-2034
  • Table 7: North America Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Country, 2021-2034
  • Table 9: Europe Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 10: Europe Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Application, 2021-2034
  • Table 11: Europe Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 14: Asia Pacific Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Application, 2021-2034
  • Table 15: Asia Pacific Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 17: Latin America Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 18: Latin America Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Application, 2021-2034
  • Table 19: Latin America Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Type, 2021-2034
  • Table 22: Middle East & Africa Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Application, 2021-2034
  • Table 23: Middle East & Africa Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Monoclonal Antibody Therapy Market Revenue (USD Billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Monoclonal Antibody Therapy Market Revenue Breakdown (USD Billion, %) by Region, 2026 & 2034
  • Figure 2: Global Monoclonal Antibody Therapy Market Value Share (%), by Type, 2026 & 2034
  • Figure 3: Global Monoclonal Antibody Therapy Market Value Share (%), by Application, 2026 & 2034
  • Figure 4: Global Monoclonal Antibody Therapy Market Value Share (%), by Distribution Channel, 2026 & 2034
  • Figure 5: Global Monoclonal Antibody Therapy Market Value (USD Billion), by Region, 2026 & 2034
  • Figure 6: North America Monoclonal Antibody Therapy Market Value (USD Billion), by Type, 2026 & 2034
  • Figure 7: North America Monoclonal Antibody Therapy Market Value Share (%), by Type, 2025
  • Figure 8: North America Monoclonal Antibody Therapy Market Value (USD Billion), by Application, 2026 & 2034
  • Figure 9: North America Monoclonal Antibody Therapy Market Value Share (%), by Application, 2025
  • Figure 10: North America Monoclonal Antibody Therapy Market Value (USD Billion), by Distribution Channel, 2026 & 2034
  • Figure 11: North America Monoclonal Antibody Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Monoclonal Antibody Therapy Market Value (USD Billion), by Country, 2026 & 2034
  • Figure 13: North America Monoclonal Antibody Therapy Market Value Share (%), by Country, 2025
  • Figure 14: Europe Monoclonal Antibody Therapy Market Value (USD Billion), by Type, 2026 & 2034
  • Figure 15: Europe Monoclonal Antibody Therapy Market Value Share (%), by Type, 2025
  • Figure 16: Europe Monoclonal Antibody Therapy Market Value (USD Billion), by Application, 2026 & 2034
  • Figure 17: Europe Monoclonal Antibody Therapy Market Value Share (%), by Application, 2025
  • Figure 18: Europe Monoclonal Antibody Therapy Market Value (USD Billion), by Distribution Channel, 2026 & 2034
  • Figure 19: Europe Monoclonal Antibody Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Monoclonal Antibody Therapy Market Value (USD Billion), by Country/ Sub-region, 2026 & 2034
  • Figure 21: Europe Monoclonal Antibody Therapy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Monoclonal Antibody Therapy Market Value (USD Billion), by Type, 2026 & 2034
  • Figure 23: Asia Pacific Monoclonal Antibody Therapy Market Value Share (%), by Type, 2025
  • Figure 24: Asia Pacific Monoclonal Antibody Therapy Market Value (USD Billion), by Application, 2026 & 2034
  • Figure 25: Asia Pacific Monoclonal Antibody Therapy Market Value Share (%), by Application, 2025
  • Figure 26: Asia Pacific Monoclonal Antibody Therapy Market Value (USD Billion), by Distribution Channel, 2026 & 2034
  • Figure 27: Asia Pacific Monoclonal Antibody Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Monoclonal Antibody Therapy Market Value (USD Billion), by Country/ Sub-region, 2026 & 2034
  • Figure 29: Asia Pacific Monoclonal Antibody Therapy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 30: Latin America Monoclonal Antibody Therapy Market Value (USD Billion), by Type, 2026 & 2034
  • Figure 31: Latin America Monoclonal Antibody Therapy Market Value Share (%), by Type, 2025
  • Figure 32: Latin America Monoclonal Antibody Therapy Market Value (USD Billion), by Application, 2026 & 2034
  • Figure 33: Latin America Monoclonal Antibody Therapy Market Value Share (%), by Application, 2025
  • Figure 34: Latin America Monoclonal Antibody Therapy Market Value (USD Billion), by Distribution Channel, 2026 & 2034
  • Figure 35: Latin America Monoclonal Antibody Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Monoclonal Antibody Therapy Market Value (USD Billion), by Country/ Sub-region, 2026 & 2034
  • Figure 37: Latin America Monoclonal Antibody Therapy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Monoclonal Antibody Therapy Market Value (USD Billion), by Type, 2026 & 2034
  • Figure 39: Middle East & Africa Monoclonal Antibody Therapy Market Value Share (%), by Type, 2025
  • Figure 40: Middle East & Africa Monoclonal Antibody Therapy Market Value (USD Billion), by Application, 2026 & 2034
  • Figure 41: Middle East & Africa Monoclonal Antibody Therapy Market Value Share (%), by Application, 2025
  • Figure 42: Middle East & Africa Monoclonal Antibody Therapy Market Value (USD Billion), by Distribution Channel, 2026 & 2034
  • Figure 43: Middle East & Africa Monoclonal Antibody Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Monoclonal Antibody Therapy Market Value (USD Billion), by Country/ Sub-region, 2026 & 2034
  • Figure 45: Middle East & Africa Monoclonal Antibody Therapy Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 46: Global Monoclonal Antibody Therapy Market Share (%), by Company, 2025